Under construction – not a live service
Sign in
Taking people in CzechiaPhase 2

Long-term study of APG777 for atopic dermatitis in people already treated with it

Tests APG777 long term in adults with atopic dermatitis who finished an earlier APG777 study.

Key facts

Who runs it
Apogee Therapeutics, Inc.
Where
Prague, CzechiaSee the siteAlso in 8 other countries, 70 sites
Trial code
Registry title
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Status
Recruiting
Phase
Phase 2
People taking part
350 people, planned
Started
14 May 2025
Expected to end
Dec 2029
Type of study
Interventional, 3 groups
Treatments tested
  • APG777
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with atopic dermatitis who finished treatment in an earlier APG777 study and may benefit from continuing APG777 long term.

Age
18 years or older
Sex
All sexes can join
Disease stage
Moderate-to-severe atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study
Earlier treatment
Must have completed the Treatment Period in a prior APG777 study (Parent Study NCT06395948) and followed the study plan. Must use the same non-medicated moisturizer throughout the study.

Main reasons for not taking part

  • Had a side effect in the Parent Study that could make continued APG777 treatment an unreasonable risk
  • Left the Parent Study early or permanently stopped the study drug
  • Uses any of the prohibited medications from the Screening Visit
  • Has other skin conditions or illnesses that could confuse the AD diagnosis or interfere with study assessments

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator's opinion, compliant with the study protocol
  • Participants who, in the Investigator's opinion, would benefit from long-term treatment with APG777
  • Use the same non-prescription non-medicated emollient/moisturizer of their choice from the last day of the Parent Study and throughout the LTE study

Who cannot take part

  • Participants who have developed an AE while participating in the Parent Study, which, in the opinion of the Investigator or of the Medical Monitor, could indicate that continued treatment with APG777 may present an unreasonable risk for the patient
  • Participants who terminated early from the Parent Study or permanently discontinued the study drug during the Parent Study
  • Use of any of the prohibited medications from Screening Visit (Visit 1) of the LTE study
  • Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or interfere with study assessments; Note: Additional protocol defined Inclusion/Exclusion criteria may apply

Where in Czechia

Also in 8 other countries, 70 sites

  • PragueHospital not named in the registryTaking people

About the trial

What the trial wants to find out

This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948).

Read full original descriptionShow less

The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.

This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.

The 3 groups in the trial

  • APG777 - Long Term Extension Treatment - 12 WeeksTreatment being tested

    Participants who achieve EASI 75 or a vIGA-AD (0, 1) at the end of the Parent Study Treatment Period, and who did not use topical rescue medication during the Parent Study will maintain the same dose regimen (dose and frequency of injections) from the Maintenance Period of the Parent Study (APG777-201).

    Treatment: APG777

  • APG777 - Long Term Extension Treatment - 24 WeeksTreatment being tested

    Participants who achieve EASI 75 or a vIGA-AD (0, 1) at the end of the Parent Study Treatment Period, and who did not use topical rescue medication during the Parent Study, will maintain the same dose regimen (dose and frequency of injections) from the Maintenance Period of the Parent Study (APG777-201).

    Treatment: APG777

  • APG777 - Open Label Escape ArmTreatment being tested

    Participants who do not achieve EASI 75 or a vIGA-AD (0, 1) at the end of the Parent Study Treatment Period, or who used topical rescue medication during the Parent Study, will be assigned to the open-label Escape Arm and will receive APG777 per protocol defined dosing regimen.

    Treatment: APG777

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
Plain-language title
Long-term study of APG777 for atopic dermatitis in people already treated with itGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 November 2026